Janssen voluntary admission: Trevicta journal ads missing PI location reference and incomplete hardcopy certification (AUTH/2870/8/16)

📅 2016 | 🖉 Dr Anzal Qurbain
📊

Key facts

Case numberAUTH/2870/8/16
CompanyJanssen-Cilag Ltd
ProductTrevicta (paliperidone palmitate 3 monthly)
Material typeTwo-page journal advertisements (PI overleaf)
Ad referencesPHGB/XEP/0516/0022; PHGB/XEP/0516/0022a; PHGB/XEP/0516/0022b; PHGB/XEP/0616/0015
Where placedThe Commissioning Review; BMJ; Nurse Prescribing; Prescriber; British Journal of Mental Health Nursing; British Journal of Psychiatry; Progress in Psychiatry
IssueMissing reference on first page to where PI could be found (PI was overleaf); final hardcopy form not certified
Root cause (as described)Job bags incorrectly uploaded into Zinc as digital-only, leading to electronic-only certification and missed final hardcopy check
Complaint received10 August 2016
Case completed23 August 2016
Applicable Code year2016
Breach clausesClause 4.7; Clause 14.1
SanctionsUndertaking received
AppealNo appeal

Download the full case report (PDF)


Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI
🎬 Expert Video Walkthrough
🎬
Video walkthrough — coming for members
Subscribe now and get expert video analysis for every case as we publish them.
Subscribe — from £299/yr
📋

What happened

  • Janssen-Cilag Ltd placed four two-page Trevicta (paliperidone palmitate 3 monthly) journal advertisements during July and August 2016.
  • The prescribing information (PI) appeared overleaf on the second page, but the first page omitted the required reference stating where the PI could be found.
  • The omission was not detected during Janssen’s copy approval/certification process.
  • An internal review found the job bags had been incorrectly uploaded into Zinc as “digital” job bags, even though the ads were both digital and hard copy.
  • As a result, the ads were electronically certified only and were not also certified in their final hardcopy form.
  • Janssen proactively notified the PMCPA (treated as a complaint under Paragraph 5.6 of the Constitution and Procedure).
⚖️

Outcome

  • Breach of Clause 4.7 was ruled (as acknowledged by Janssen).
  • Breach of Clause 14.1 was ruled (as acknowledged by Janssen).
  • No appeal.
  • Sanction recorded: Undertaking received.
🔒

Unlock the full case analysis

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value
£249/year
Annual — save £99
or
£29/mo
Monthly
Join Now — Instant Access

⭐ Business Intelligence Access

See the full compliance picture for every pharma company

291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export.

Request Access →
⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week — free.

Subscribe Free
🎓 AQP Training